OnDosis, a Swedish life science company, and Recipharm, have entered an agreement for the formulation development of an ADHD treatment for the U.S. market. The new ADHD treatment will be developed by Recipharm’s Centre of Excellence in Oral Solids and will leverage OnDosis’ technology which integrates oral drugs in form of micro units and individualized dosing, in a handheld device. The advantages are simplified titration, more accurate dosing and the ability to track dosing and treatment res...